NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
Last trade$7.25
Day change+$0.57 (+8.53%)
Day range$6.35 – $7.25
Volume60,438
Market cap$31M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$30.59M
Price / earnings
—
Price / book
5.56×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.58×
Profitability
Earnings per share
-$8.95
Return on assets
-422.37%
Return on equity
-744.5%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
2.31×
Quick ratio
2.31×
Cash ratio
2.08×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$42.79M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NXTC, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$4.43M
$2.59M
$3.27M
$2.96M
$2.81M
$3.2M
$3.73M
$3.55M
Research and development
$4.54M
$7.43M
$6.83M
$6.8M
$6.14M
$24.09M
$7.9M
$8.9M
Total operating expenses
$6.92M
$15.09M
$10.11M
$9.76M
$8.95M
$27.29M
$11.62M
$12.46M
Operating income
-$6.92M
-$15.09M
-$10.11M
-$9.76M
-$8.95M
-$27.29M
-$11.62M
-$12.46M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$6.85M
-$14.89M
-$9.8M
-$9.44M
-$8.62M
-$26.81M
-$10.98M
-$11.6M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$6.85M
-$14.89M
-$9.8M
-$9.44M
-$8.62M
-$26.81M
-$10.98M
-$11.6M
Net income attributable to common shareholders
-$6.85M
-$14.89M
-$9.8M
-$9.44M
-$8.62M
-$26.81M
-$10.98M
-$11.6M
EBITDA
-$8.96M
-$9.75M
-$9.82M
-$9.39M
-$8.41M
-$26.66M
-$10.97M
-$11.78M
Basic earnings per share
-$1.29
-$2.80
-$1.87
-$2.37
-$3.22
-$11.29
-$4.70
-$4.97
Diluted earnings per share
-$1.29
-$2.80
-$1.87
-$2.37
-$3.22
-$11.29
-$4.70
-$4.97
Recent news
Company coverage with links to the original publishers.
Law firm Halper Sadeh LLC is investigating whether NextCure, Inc. obtained a fair price in its proposed merger with Avere Therapeutics, where NextCure shareholders would own only approximately 1.21% of the combined company. The investigation examines potential violations of federal securities laws and breaches of fiduciary duty regarding fair pricing, sales process integrity, and disclosure adequacy.
NextCure Inc. announced a definitive merger agreement with privately-held Avere Therapeutics in an all-stock transaction. The combined company will operate as Avere Therapeutics and trade on Nasdaq under ticker 'AVRX'. Avere's lead program AVR-001, an oral IL-23 receptor antagonist, received $320 million in concurrent private investment. The merger is expected to close in H2 2026, with NextCure stockholders owning approximately 1.21% of the combined entity.
NextCure (NASDAQ: NXTC) shares rose 2.10% in premarket trading Wednesday following positive Phase 1 clinical data for SIM0505, an antibody-drug conjugate developed with Simcere Zaiming Pharmaceutical for treating platinum-resistant ovarian cancer and uterine serous carcinoma. However, the stock remains deeply oversold with technical indicators showing a bearish trend despite the positive catalyst.
NextCure announced Phase 1 dose escalation data for SIM0505 (CDH6 ADC) expected in Q2 2026 and expanded higher dose cohorts for LNCB74 (B7-H4 ADC). The company reported preliminary year-end 2025 cash position of $41.8 million and expects resources to fund operations into the first half of 2027. LNCB74 proof-of-concept data timeline was delayed to second half of 2026 to accommodate enrollment.
NextCure reported a Q2 2025 net loss of $26.8 million, primarily due to a $17.0 million license fee for SIM0505. The company advanced its lead clinical programs LNCB74 and SIM0505, with proof-of-concept data expected in the first half of 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.